# CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes

> **NCT05931276** · PHASE3 · RECRUITING · sponsor: **VA Office of Research and Development** · enrollment: 2540 (estimated)

## Conditions studied

- End-Stage Kidney Disease
- End-Stage Renal Disease

## Interventions

- **DRUG:** Metoprolol Succinate
- **DRUG:** Carvedilol

## Key facts

- **NCT ID:** NCT05931276
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-22
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 2540 (ESTIMATED)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05931276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05931276, "CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05931276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*